PT - JOURNAL ARTICLE AU - Katayama, Yu AU - Miyawaki, Yoshia AU - Shidahara, Kenta AU - Nawachi, Shoichi AU - Asano, Yosuke AU - Katsuyama, Eri AU - Katsuyama, Takayuki AU - Takano-Narazaki, Mariko AU - Matsumoto, Yoshinori AU - Oguro, Nao AU - Yajima, Nobuyuki AU - Ishikawa, Yuichi AU - Sakurai, Natsuki AU - Hidekawa, Chiharu AU - Yoshimi, Ryusuke AU - Ohno, Shigeru AU - Ichikawa, Takanori AU - Kishida, Dai AU - Shimojima, Yasuhiro AU - Sada, Ken-ei AU - Wada, Jun AU - Thom, David H AU - Kurita, Noriaki TI - Discontinuity of care and trust in usual physician among patients with systemic lupus erythematosus AID - 10.1101/2024.03.13.24304255 DP - 2024 Jan 01 TA - medRxiv PG - 2024.03.13.24304255 4099 - http://medrxiv.org/content/early/2024/03/15/2024.03.13.24304255.short 4100 - http://medrxiv.org/content/early/2024/03/15/2024.03.13.24304255.full AB - Importance Patient trust plays a central role in the patient-physician relationship; however, the impact of outpatient visits with a covering physician (covered visits) on the level of trust in usual physician among patients with chronic conditions is unknown.Objective To determine whether the number of outpatient visits with a covering rheumatologist is associated with patient trust in the usual rheumatologist.Design Cross-sectional study.Setting This study used data from the TRUMP2-SLE project conducted at five academic medical centers in Japan.Participants The participants were Japanese adults with systemic lupus erythematosus who met the 1997 revised classification criteria of the American College of Rheumatology.The enrollment period was February 2020 to October 2021.Exposure Outpatient visits with a covering rheumatologist in the past year.Main Outcomes and Measures The main outcome was patient trust in their usual rheumatologist, assessed using the 11-item Japanese version of the modified Trust in Physician Scale (range 0–100). A general linear model with cluster robust variance estimation was used to evaluate the association between the number of outpatient visits with a covering rheumatologist and the patient’s trust in their usual rheumatologist.Results Of the 515 enrolled participants, 421 patients with systemic lupus erythematosus were included in our analyses.The median age was 47.0 years, and 87.2% were women. Thirty-nine usual rheumatologists participated in this study. Patients were divided into groups according to the number of outpatient visits with a covering rheumatologist in the past year as follows: no visits (59.9%; reference group), one to three visits (24.2%; low-frequency group), and four or more visits (15.9%; high-frequency group). The median Trust in Physician Scale score was 81.8 (interquartile range 72.7–93.2). Both the low-frequency and high-frequency groups exhibited lower trust in their usual rheumatologist (mean difference: -3.03 [95% confidence interval -5.93 to -0.80], -4.17 [95% confidence interval -7.77 to -0.58, respectively]).Conclusions and Relevance This study revealed that the number of outpatient visits with a covering rheumatologist was associated with lower trust in a patient’s usual rheumatologist. Further research is needed to address the potential adverse effects of physician coverage on trust in patient’s usual rheumatologist.Question Is the number of outpatient visits with a covering rheumatologist associated with the loss of trust in usual rheumatologist in patients with systemic lupus erythematosus (SLE)?Findings This multicenter cross-sectional study which included 421 patients with SLE revealed that the number of outpatient visits with a covering rheumatologist in the past year was associated with lower levels of trust in the usual rheumatologist.Meaning This study alerts us about the need to prepare for the possible adverse effects of unavoidable outpatient coverage.Competing Interest StatementDr Kurita reported receiving grants from the Japan Society for the Promotion of Science, consulting fees from GlaxoSmithKline K.K., and payments for speaking at and participating in educational events from Chugai Pharmaceutical Co, Ltd, Sanofi K.K., Mitsubishi Tanabe Pharma Corporation, and the Japan College of Rheumatology. Dr Sada reported receiving a research grant from Pfizer Inc and a payment for speaking at and participating in educational events from GlaxoSmithKline K.K. Dr Wada reported receiving speaker honoraria from Astra Zeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Kyowa Kirin, Novo Nordisk, and Mitsubishi Tanabe, and receives grant support from Bayer, Chugai, Kyowa Kirin, Otsuka, Shionogi, Sumitomo, and Mitsubishi Tanabe. Dr Matsumoto reported receiving grants from Asahi Kasei Pharma, Taisho and AbbVie, receives speaker honoraria from Astra Zeneca, Asahi Kasei Pharma, GlaxoSmithKline and Pfizer and receives a payment for participating in educational events from GlaxoSmithKline.Funding StatementThis study was funded by JSPS KAKENHI Grant Numbers 19KT0021 and 22K19690Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of Okayama University Hospital gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe dataset analyzed in this paper is available from the corresponding author on reasonable request.